Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...
The AAPM consensus guidelines evaluated neuromodulation technologies for functional restoration and pain relief in neurologic ...
New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...
From joint replacement and Deep TMS for depression to targeted therapy for cancer, experts highlight top U.S. medical ...
In the technical language of clinicians, when speaking of the patient's suffering or discomfort, we traditionally make a ...
AtaiBeckley Inc. recently announced that the last patient has been dosed in Elumina, its 156-patient, international Phase 2b ...
Government programs that put artists to work and their connections to community across generations explored at Delaware Art ...
Secret Life of Mom on MSN
The survival secrets Americans learned during the Great Depression
The American spirit survived the Great Depression by being built on community, mutual aid, and hard-won ingenuity. The post ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...
The decision, made by the ministry on April 28, marks the first time art therapy has transitioned from an informal or ...
Considering they’re a class of drugs known for making you smaller, GLP-1 receptor agonists are only getting bigger. As many ...
Depression doesn't always look like sadness at your job. Don't ignore these subtle warning signs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results